Shared on 25 Feb 26
Fair value Decreased 33%Moving from "Science Fiction" to "Science Fact": Recursion’s Q4 Validates a Hyper-Growth Inflection Point
30 viewsusers have viewed this narrative update
Recursion PharmaceuticalsRXRX
Fair Value
US$8.38
Share price25 Feb
US$3.5657.5% undervalued intrinsic discount
1Y-32.58%
7D-6.32%
Moving from "Science Fiction" to "Science Fact" – A Bullish Valuation Case
TA
"Any sufficiently advanced technology is indistinguishable from magic." — I invest in making that magic real. Focused purely on the shift from Science Fiction to Science Fact. No specific sector. Just paradigm shifts.
Published
02 Dec 25
Updated
25 Feb 26
Views
493
Invested